These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Evaluation of a fluorimetric for determining the activity of amylo-1,6-glucosidase in leukocytes for confirming the diagnosis of glycogen storage disease type III].
    Author: Miadi-Messaoud H, Mili A, Ben Khalifa H, Limem K.
    Journal: Ann Biol Clin (Paris); 2011; 69(1):41-5. PubMed ID: 21463994.
    Abstract:
    The confirmation of type III glycogen storage disease diagnosis is based on histological explorations on to live and/or muscle biopsies that induce some problems of delay and sensitivity. The purpose of this study was to evaluate a fluorimetric technique for the determination of amylo-1,6-glucosidase activity in leukocytes, in order to confirm the diagnosis of type III glycogen storage disease. The method consists in measuring the glucose released by hydrolysis of phosphorylase dextrin limit in the presence of cellular extracts, in 50 volunteers and 18 patients suspected of glycogenosis. Benefits of this technique are linearity, precision (CV = 1.68%), exactitude (CI = 0.17%), its high sensitivity (Sn = 100%) and its specificity (Sp = 96.1%). The phosphorylation of dextrin limit test allows measurement of both transferasic (α-1,4) and hydrolytic (α-1,6) enzyme activities. In conclusion, this non-invasive, and inexpensive assay, can be applied to most of the clinical biology laboratories. Comparison with radiometry and immunoblot indicate a noticeable discriminating capacity between normal subjects, patients with type I and VI glycogenosis, and patients' subgroups of type III glycogenosis.
    [Abstract] [Full Text] [Related] [New Search]